Skip to main content

Advertisement

Table 4 Clinicopathological factors in relation to EDN3 protein expression

From: Frequent loss of endothelin-3 (EDN3) expression due to epigenetic inactivation in human breast cancer

  EDN3 expression
Variables Numbera Low (IRS < 8) High (IRS ≥ 8) P valueb
Clinicopathological factors     
   Age at diagnosis     
≤ 59 years 83 36 47 0.632
> 59 years 67 32 35  
   Tumour sizec     
pT1 48 21 27 0.728
pT2 to pT4 100 47 53  
   Lymph node statusc     
pN0 67 29 38 0.742
pN1 to pN3 80 37 43  
   Histological grade     
G1 and G2 83 35 48 0.408
G3 66 33 33  
   Histological type     
Ductal 122 53 69 0.385
Lobular 12 5 7  
Other 16 10 6  
   Tumour focality     
Unifocal 130 61 69 0.467
Multifocal 19 7 12  
   Oestrogen receptor     
Negative (IRSd ≤ 2) 38 19 19 0.698
Positive (IRS > 2) 83 45 38  
   Progesterone receptor     
Negative (IRSd ≤ 2) 85 41 44 0.704
Positive (IRS > 2) 40 21 19  
   Her2 status     
Negative (IHC: 0; 1+) 105 46 59 0.169
Positive (IHC: 2+; 3+) 23 14 9  
  1. aOnly female patients with primary invasive breast cancer were included. bFisher exact test (two-sided). cAccording to the UICC (Union Internationale contre le Cancer): TNM Classification of Malignant Tumours [19].dImmunoreactivity score (IRS) according to Remmele and Stegner [24]. EDN3, endothelin-3; IHC, immunohistochemistry.